The MRCF’s investors include Australia’s leading superannuation funds and Australia’s largest and most successful biotechnology company, CSL.

By investing in biotech discoveries, our superannuation funds are generating long-term, superior returns on behalf of their superannuate investors. This is a virtuous circle where returns are generated for our aging population, while at the same time, the capital superannuates invest, supports health-enhancing discoveries.

Australia and New Zealand are two of the world’s leaders in biomedical research and drug discovery. The creation of medical devices represents Australia’s largest manufacturing export industry, with huge potential for growth and expansion in the future.


By supporting the MRCF, investors are seeking out superior returns from a sophisticated and growing sector. As well as offering strong financial returns, their investment supports job creation, economic growth and improved health outcomes for all.